<DOC>
	<DOCNO>NCT00912639</DOCNO>
	<brief_summary>The purpose study evaluate response rate patient taxane-pretreated recurrent breast cancer receive paclitaxel load polymeric micelle ( Genexol-PM ) .</brief_summary>
	<brief_title>A Clinical Trial Paclitaxel Loaded Polymeric Micelle Patients With Taxane-Pretreated Recurrent Breast Cancer</brief_title>
	<detailed_description>Genexol-PM novel Cremophor EL-free polymeric micelle formulation paclitaxel . This single arm , multicenter phase IV study design evaluate response rate , toxicity , progression free survival tumor control rate Genexol-PM patient Taxane-pretreated recurrence breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Women age &gt; =18 year 2. WHO ( ECOG ) performance status 02 3 . Estimated life expectancy &gt; =3 month 4 . Have give write informed consent available prolong followup 1 . Patients previous chemotherapy recurrent breast cancer 2 . Breast cancer recurrence within 12 month taxane treatment 3 . Her2/neu expression 4 . Patients malignancy ( breast cancer ) within last 5 year , except adequately treat situ carcinoma cervix basal cell , squamous cell carcinoma skin . 5 . Brain metastasis 6. uncontrolled infection , medically uncontrollable heart disease 7. serious medical illness prior malignancy 8 . Pregnant lactate woman exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>Genexol-PM</keyword>
</DOC>